Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L, Reck M. Edelman MJ, et al. Among authors: kaleta r. J Clin Oncol. 2013 Jun 1;31(16):1990-6. doi: 10.1200/JCO.2012.45.3282. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589560 Clinical Trial.
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Kunz PL, et al. Among authors: kaleta r. Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3. Epub 2012 Feb 14. Invest New Drugs. 2012. PMID: 22331549 Free PMC article. Clinical Trial.
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Tsimberidou AM, et al. Among authors: kaleta r. J Hematol Oncol. 2021 Aug 18;14(1):127. doi: 10.1186/s13045-021-01132-z. J Hematol Oncol. 2021. PMID: 34407844 Free PMC article. Clinical Trial.
Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase.
Zmudzinski M, Rut W, Olech K, Granda J, Giurg M, Burda-Grabowska M, Kaleta R, Zgarbova M, Kasprzyk R, Zhang L, Sun X, Lv Z, Nayak D, Kesik-Brodacka M, Olsen SK, Weber J, Hilgenfeld R, Jemielity J, Drag M. Zmudzinski M, et al. Among authors: kaleta r. Sci Rep. 2023 Jun 6;13(1):9161. doi: 10.1038/s41598-023-35907-w. Sci Rep. 2023. PMID: 37280236 Free PMC article.
Optimized Ebselen-Based Inhibitors of Bacterial Ureases with Nontypical Mode of Action.
Macegoniuk K, Tabor W, Mazzei L, Cianci M, Giurg M, Olech K, Burda-Grabowska M, Kaleta R, Grabowiecka A, Mucha A, Ciurli S, Berlicki Ł. Macegoniuk K, et al. Among authors: kaleta r. J Med Chem. 2023 Feb 9;66(3):2054-2063. doi: 10.1021/acs.jmedchem.2c01799. Epub 2023 Jan 20. J Med Chem. 2023. PMID: 36661843 Free PMC article.
12 results